Eslicarbazepine original manufacturer information and related production background introduction

Eslicarbazepine acetate (Eslicarbazepine acetate) is an anti-epileptic drug mainly used to treat partial-onset epilepsy in adults. Its original manufacturer is the Portuguese pharmaceutical company BIAL. The company was founded in 1924 and is headquartered in Trofa, Portugal. It is one of the largest pharmaceutical companies in Portugal. BIALFocuses on the research and development of central nervous system (CNS) diseases and is committed to providing innovative treatment options for patients around the world.

The research and development of eslicarbazepine began in the 1990s and was led by BIAL. This drug is a derivative of oxcarbazepine, a member of the dibenzazepine class of compounds. Its active metabolite is (S)-(+)-licarbazepine, which has anti-epileptic effects. Eslicarbazepine was approved in Europe in 2009 and marketed under the brand names Zebinix® and Exalief®. In the United States, eslicarbazepine is marketed by Sunovion Pharmaceuticals Inc. under the brand name Aptiom®.

Eslicarbazepine is produced using standardized manufacturing processes to ensure product quality and consistency. The drug is administered orally and is rapidly absorbed into the body and converted into the active metabolite (S)-(+)-licarbazepine, which exerts anti-epileptic effects. Its main mechanism is to control epileptic seizures by stabilizing the inactivation state of voltage-gated sodium channels and reducing neuronal excitability.

Currently, eslicarbazepine has been launched in many countries and regions, including Europe, the United States, Canada, etc. As patents expire, the availability and economics of the drug improve with the emergence of generic versions. However, patients should pay attention to their quality and origin when using generic drugs to ensure the safety and effectiveness of their treatment.

Reference materials:https://www.drugs.com/